OBR Daily Commentary

forumImage

Many Women Get Unnecessary Mammograms Before Breast Reduction Surgery

(U-M/M Health Lab) Jan 29, 2019 - Nearly one-third of younger women without a known cancer risk receive the screening before breast reduction surgery, a test that can do more harm than good. Each year, thousands of younger women with no known risk of breast cancer get mammograms before having breast reduction surgery. Patients receive the exam, often at the suggestion of their doctors, when the best recommendation says to avoid routine mammograms before elective breast surgery unless a specific concern exists.

Read Article arrow

Howard S. Hochster, MD (Posted: January 31, 2019)

quotesGood argument for tort reform. No surgeon wants to be in court for doing the wrong surgical procedure if an incidental breast cancer is found. Juries and plaintiffs don’t tend to accept guidelines in the face of actual damages to a person. quotes

Add Comment 1 Comment
forumImage

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

(AbbVie) Jan 18, 2019 - The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents. The study did not show statistically-significant progression-free or overall survival benefit with ibrutinib in combination versus the placebo combination study arm. Metastatic pancreatic cancer is one of the most aggressive and deadliest forms of cancer, with an estimated 5-year survival of less than 5 percent. IMBRUVICA is currently approved by the U.S. FDA in six disease areas with nine treatment indications and has cumulatively treated more than 135,000 patients globally in clinical practice and trials

Read Article arrow

Howard S. Hochster, MD (Posted: January 22, 2019)

quotesAnother phase 3 trial of Gem-Abraxane with or without your favorite targeted agent. No particular rationale for using BTK inhibitor, ibrutinib, or patient selection for this pathway. And another negative trial without benefit. Let's get smarter.quotes

Add Comment 1 Comment
forumImage

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

(MarketWatch) Jan 14, 2019 - Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S. “This new indication for CABOMETYX is an important treatment advance for patients with this aggressive form of liver cancer, a community in need of new therapeutic options,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “This approval is an important milestone as we continue to explore how CABOMETYX may benefit people with difficult-to-treat-cancers beyond renal cell carcinoma. We would like to thank the patients and clinicians who participated in CELESTIAL and to acknowledge the team at the FDA for their continued collaboration during the review of our application.”

Read Article arrow

Howard S. Hochster, MD (Posted: January 15, 2019)

quotesAnother TKI for HCC! We now have 3 agents with variable tolerability profiles. Good news for patients as we have more choices. Now we need more studies on how to incorporate these agents with local therapies including resection, radiation, TACE, TARE and also in combination with immunotherapy. Exciting opportunities. quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...